Skip to content Skip to footer
Subscribe Now
Viewpoints_Dennis Williams
VIEWPOINTS
PharmaShots Interview: Adaptimmune’s Dennis Williams Shares Insight About the Company’s Pathway to Bringing the First-Ever TCR T-Cell Therapy for Solid Tumors to Market
In an interview with PharmaShots, Dennis Williams, SVP Late-stage Development at Adaptimmune shared his views on the Company's unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform and their pathway to bringing the first-ever TCR T-cell therapy for solid tumors to market along with an overview about their industry-leading T-cell therapy pipeline in solid tumors.…
August 16, 20210Comments
Viewpoints_Konstantin Mehl
VIEWPOINTS
PharmaShots Interview: Kaia Health’s Konstantin Mehl Shares Insight on the Funding to Transform the Treatment for MSK and COPD
In an interview with PharmaShots, Konstantin Mehl, President, CEO, and Founder at Kaia Health shared his views on the grant of $75M Series C funding to expand clinical capabilities & transform the treatment path for musculoskeletal (MSK) and chronic obstructive pulmonary disease (COPD) care in the US and EU. Shots: The funding will extend the offering within EU and…
August 11, 20210Comments
Viewpoints_Jan Wehkamp
VIEWPOINTS
PharmaShots Interview: Janssen’s Jan Wehkamp Shares Insight on the Data from UNIFI Study of Stelara Presented at ECCO
In an interview with PharmaShots, Jan Wehkamp, M.D., Vice President, Disease Area Leader, Gastroenterology at Janssen Research & Development shared his views on the data regarding the safety & efficacy of Stelara (ustekinumab) for UC patients, including long-term symptomatic & corticosteroid-free remission rates from the UNIFI study. Shots: The P-III UNIFI study evaluates the safety & efficacy…
August 9, 20210Comments
Viewpoints_Laurent Debussche
VIEWPOINTS
PharmaShots Interview: Sanofi’s Laurent Debussche Shares Insight on the Need of SERDs for ER+ Breast Cancer
In an interview with PharmaShots, Laurent Debussche, Global Head of Molecular Oncology Research Therapeutic Area at Sanofi shares insight on the SERDs data being presented at ASCO 2021 and highlight the need for this type of innovation for ER+ breast cancer Shots: Sanofi has presented the data from P-I AMEERA-1 study evaluating amcenestrant in combination with palbociclib &…
August 9, 20210Comments
Viewpoints_Kelly Pokuta and April Kunze
VIEWPOINTS
PharmaShots Interview: Prime Therapeutics’ Kelly Pokuta and April Kunze Share Insight on Medical Drug Management Program
In an interview with PharmaShots, Kelly Pokuta, Vice President of Pharmaceutical Trade Relations, and April Kunze, Senior Director, Clinical Formulary Development & Trend Management Strategy at Prime therapeutics share their views on the MedDrive as a first-of-its-kind medical drug management program uniquely aligned with Blue Plan clients. Shots: Prime introduced the first-of-its-kind medical drug management…
August 3, 20210Comments
Viewpoints_Bassil I. Dahiyat
VIEWPOINTS
PharmaShots Interview: Xencor’s Bassil I. Dahiyat Shares Insight on the US FDA’s Approval of COVID-19 Antibody Treatment Leveraging its Technology
In an interview with PharmaShots, Dr. Bassil I. Dahiyat, President and CEO of Xencor shared his views on the company's collaborations with BMS and its Xtend XmAb technology. He also shed light on the EUA of Sotrovimab for COVID-19. Shots: The FDA has granted EUA to Vir and GSK's sotrovimab, which was engineered with Xencor's XmAb…
August 3, 20210Comments
Viewpoints_Dr. Lotus Mallbris
VIEWPOINTS
PharmaShots Interview: Eli Lilly’s Dr. Lotus Mallbris Shares Insight on the Data of Taltz and Olumiant Presented at EULAR 2021
In an interview with PharmaShots, Dr. Lotus Mallbris, M.D., Ph.D., Vice President of Immunology Development at Lilly shared her views on the abstracts demonstrating data on the use of Taltz and Olumiant in rheumatic diseases, including psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) for Taltz, and rheumatoid arthritis (RA) for Olumiant.  Shots: Lilly reported that key data from Taltz (ixekizumab) & Olumiant (baricitinib) is highlighted at the virtual EULAR…
August 2, 20210Comments

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]